Date: 2017-02-01
Type of information: Results
phase: preclinical
Announcement: results
Company: Allergy Therapeutics (UK)
Product: Polyvac® Peanut
Action
mechanism: immunotherapy product. This peanut vaccine is focussed on a subcutaneous application of recombinant peanut allergen coupled with a state-of-the-art VLP adjuvant to increase the safety and efficacy profile. This approach aims to induce protective immunity, enabling shorter therapy duration and an enhanced safety profile and thus has significant implications for peanut allergy therapy with the potential to redefine the market for food allergy products. Alternative peanut vaccines in development often require repeated and long-lasting exposure transdermally or orally which may limit patient adherence.
Disease: peanut allergy
Therapeutic area: Allergic diseases
Country:
Trial details:
Latest
news: * On February 1, 2017, Allergy Therapeutics announced positive results from preclinical research into its unique therapeutic peanut allergy vaccine, Polyvac® Peanut. The company will now progress the vaccine in accordance with its stated strategic plan when funding the programme and will proceed to Phase I development following completion of a first in man safety data trial.
The findings demonstrate that a single dose of the Company's virus-like-particles (VLP) adjuvant combined with recombinant peanut allergen successfully protected against anaphylaxis when challenged with peanut. Additionally, when examining symptom scores in the investigational model, those vaccinated with the candidate vaccine exhibited no symptoms compared to placebo. Furthermore, the safety profile of the product was evaluated via an intravenous challenge and found that the vaccine itself did not induce anaphylaxis in peanut sensitised subjects (a hypoallergenic vaccine). Allergy Therapeutics intends to publish full data from this study in a peer-reviewed journal.
